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1. Introduction 
Site-directed mutagenesis (SDM) is undoubtedly one of the most powerful techniques in 
molecular biology. In this chapter, we will describe the use of SDM in the study of the 
human inherited metabolic disorder, Galactosemia (Type I, II, and III) and the development 
of novel therapies for the disease. This powerful technique not only helped confirm 
suspected GAL gene mutations in Galactosemia, but also played a significant role in 
unraveling the catalytic mechanisms of the GAL enzymes in the conserved Leloir pathway 
of galactose metabolism. To date, more than thirty disease-causing mutations in the human 
GAL genes have been characterized in great detail; and these findings have paved the way 
for innovative, state-of-the-art therapies, such as chaperone therapy. Recently, in order to 
optimize small molecule GALK inhibitors for the treatment of Type I Galactosemia, we have 
employed SDM to identify amino acids of the GALK enzyme that interact with its selective 
inhibitors. These studies exemplified the expanding roles of SDM in innovative drug design 
and in kinase inhibitor selectivity. 
2. Background 
2.1 What is galactosemia? 
Galactose is a hexose that differs from glucose only by the configuration of the hydroxyl 
group at the carbon-4 position. Often present as an anomeric mixture of α-D-galactose and 
β-D-galactose, this monosaccharide exists abundantly in milk, dairy products and many 
other food types such as fruits and vegetables (Acosta and Gross, 1995; Berry et al., 1993). 
However, galactose can also be produced endogenously in human cells, mainly as products 
of glycoprotein and glycolipid turnover.(Berry et al., 1995, 2004). Once freely present inside 
the cells, β-D-galactose is epimerized to α-D-galactose through the action of a mutarotase 
(Beebe and Frey, 1998; Thoden and Holden, 2002a). α-D-galactose is then metabolized by the 
Leloir pathway (Leloir 1951), an evolutionarily conserved biochemical pathway which 
begins with the phosphorylation of galactose by the enzyme galactokinase (GALK) to form 
galactose-1 phosphate (gal-1P) (Cardini and Leloir, 1953). Gal-1P is subsequently, together 
with the substrate UDP-glucose, converted by galactose-1-phosphate uridylyltransferase 
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(GALT) to form UDP-galactose and glucose-1 phosphate (glu-1P) (Kalckar et al., 1953). The 
Leloir pathway is completed by reversibly forming UDP-glucose from UDP-galactose via 
UDP-galactose-4-epimerase (GALE) (Leloir 1953; Darrow and Rodstorm, 1968). Inherited 
deficiencies of GALK, GALT, and GALE activities in humans have all been observed, 
studied, and reviewed extensively (Bosch et al., 2002; Elsas 1993; Fridovich-Keil et al., 
1993a). The clinical manifestations of each enzyme deficiency, however, differ markedly 
(Berry et al., 1995; Berry and Elsas, 2011; Fridovich-Keil et al., 1993a; Lai et al., 2009;). For 
instance, patients with GALK deficiency (MIM 230200) (Type II Galactosemia) have the 
mildest clinical consequences, as they may present only with cataracts (Bosch et al., 2002). 
On the other hand, GALT-deficiency (MIM 230400) (Type I or Classic Galactosemia) is 
potentially lethal in infancy, if undiagnosed and untreated, and is also associated with long-
term, organ-specific complications (Berry et al., 1995). GALE-deficiency (MIM 230350) (Type 
III Galactosemia) has been somewhat controversial with regards to clinical manifestations, 
as this disorder is rare; and information is mostly derived from case reports (Fridovich-Keil 
et al., 1993a). Until newborn screening for GALE deficiency is available, the natural history 
will likely remain unknown. The differences in clinical outcome between GALT and GALK 
deficiencies reflect the differences in tissue response to the characteristic changes in the 
levels of galactose metabolites as a result of the respective enzyme deficiencies. 
2.2 How are the different types of galactosemia detected and diagnosed? 
Newborn screening programs worldwide have greatly facilitated the early detection of 
Galactosemia (Kaye et al., 2006; Levy 2010). The screening tests often involve the 
detection of elevated level of blood galactose and/or specific GAL enzyme in the dried 
blood spots on filter paper. Elevated galactose will detect GALK deficiency and GALT 
deficiency, but it may not detect GALE deficiency. Other states screen for GALT 
activity, and may therefore diagnose Type I Galactosemia. However, this screen will 
miss GALK and GALE deficiency. The final diagnosis is secured once the specific 
enzyme deficiency is confirmed by enzymatic assays or by DNA genotyping; these tests 
are available commercially in the USA (http://www.ncbi.nlm.nih.gov/sites/ 
GeneTests/, Tests #3437, #2229 and #53782). 
2.3 What are the current treatments for galactosemia, and what is the outlook for 
patients? 
The main aspect of management for all forms of Galactosemia is withdrawal of 
lactose/galactose from the diet as soon as the diagnosis is made, or even considered (Segal 
1995). In infants, this means the replacement of breast/cow milk with soy-based formula. 
However, it has become clear that, despite early detection and (early) dietary intervention, 
there still is a significant burden of the disease, particularly for Classic Galactosemia where 
chronic problems persist through adulthood. The most common medical complications of 
Type I Galactosemia are speech dyspraxia, ataxia, premature ovarian insufficiency, and 
intellectual deficits, which are rarely seen in other forms of galactosemia (Waggoner et al., 
1990; Waisbren et al., 2011). GALK deficiency (Type II Galactosemia) is managed also with 
lactose/galactose restriction, though the complications are mainly confined to the eye 
(cataracts) (Bosch et al., 2002). GALE deficiency is treated similarly, though complications of 
this deficiency may not be preventable with such restriction, as is GALT deficiency 
(Fridovich-Keil et al., 1993a). 
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3. Use of SDM to confirm disease-causing mutations in human GALT, GALK, 
and GALE genes identified clinically 
3.1 The issues 
Advances in federal and state newborn screening programs worldwide have resulted in the 
inclusion of the potentially lethal disorder, Galactosemia, in the list of diseases for which 
newborns are screened. Very often, once an affected newborn is identified by the 
biochemical assays, it is helpful to know the genotype of GAL gene involved because there 
appears to be a genotype-phenotype correlation for a few selected GAL gene mutations. The 
confirmation of the GAL genotypes in the affected patients will provide better prognosis. 
Additionally, a few well-characterized GAL enzyme variants have been shown to retain 
significant residual enzyme activities. Consequently, patients with selected mutations might 
benefit from novel therapies, such as chaperone therapies. 
Unfortunately many patients with Galactosemia identified to-date have novel (private) 
nucleotide changes in their GAL genes. For instance, the GALT gene database set up by the 
ARUP Laboratories (Salt Lake City, USA) has recorded over 200 nucleotide changes of the 
GALT gene identified in patients with Type I Galactosemia (www.arup.utah.edu/database/ 
GALT/GALT_welcome.php). Without clinical correlation, it is impossible to tell if any of these 
novel changes actually results in impaired GALT enzyme activities seen in the patients. 
Moreover, many patients are compound heterozygous for the GAL gene mutations. In other 
words, a single patient may have a unique nucleotide change in each of the two GAL alleles; 
and it is difficult to conclude which one is responsible for the reduction in total enzyme 
activity. Thus there is a real need to perform in vitro expression studies of the identified 
“variant” GAL genes. 
3.2 Research design 
Our laboratory and others have largely used similar strategies in confirming the suspected 
human GAL gene mutations in patients with Galactosemia (Fridovich-Keil et al., 1995a; Lai 
et al., 1999; Reichardt et al., 1992;). In almost all cases, we sub-cloned the cDNA of the 
respective GAL gene into expression plasmid vectors, before we performed SDM of the sub-
cloned fragments to obtain “mutant” cDNAs with the same sequence changes observed in 
patients. We then expressed the wild-type and mutated cDNAs in heterologous expression 
systems, such as Escherichia coli, Saccharomyces cerevisiae or even mammalian expression 
systems. Subsequently, we tested for differences in kinetic parameters of the GAL enzymes, 
such as KM and Vmax, and the expression efficiencies, such as protein and/or mRNA 
abundances, between mutant and control cDNAs. 
3.3 The results 
The primary goal for expression analysis of the suspected disease-causing mutations in the 
GAL genes is to show that the nucleotide changes observed are causing impaired GAL 
enzyme activities and could therefore be the causes for the diseases. In addition, in the 
course of the analysis, kinetic parameters of the variant enzymes are often determined, 
which are expected to help advance the structural knowledge of the GAL enzymes. 
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3.3.1 Type I (GALT-deficiency) galactosemia 
As mentioned above, more than 200 nucleotide changes in the GALT gene have been 
identified so far,  mostly single nucleotide substitutions. The most common human GALT 
mutation, Q188R, is detected in over 70% of galactosemic patients in Europe and North 
America. The Q188R mutation is associated with a poor clinical outcome, even with a 
galactose-restricted diet (Guerrero et al., 2000; Murphy et al., 1999; Webb et al., 2003). K285N 
is the second most common mutation found in patients in Europe, especially in the countries 
of central and Eastern Europe, where it can account for up to 34% of GALT  alleles (Greber-
Platzer et al., 1997; Kozak et al., 2000). In the African-American population, the S135L 
mutation is predominant. The corresponding enzyme leads to a relatively benign outcome, 
if the mutation is identified and the patient is treated with a galactose-restricted diet in the 
newborn period (Lai et al., 1996, 2001; Landt et al., 1997). A more common mutation, N314D, 
occurs in all populations mentioned above and can lead to two different phenotypes, 
depending on the presence or absence of a 4-bp deletion in the coding region for the 
carbohydrate response element. When N314D is associated with a four-nucleotide deletion 
in the promoter region (the Duarte type 2), homozygosity for N314D and this altered 
promoter region causes a 50% decrease of GALT activity, with a mild or even undetected 
phenotype (Elsas et al., 1994). In the absence of this deletion in the promoter, homozygosity 
for the N314D missense mutation (the Los Angeles variant) results in normal GALT in 
erythrocytes (Shin et al., 1998). A 5-kb deletion is found so far exclusively in Ashkenazi 
Jewish patients (Coffee et al., 2006). 
Due to its frequency among GALT-deficiency galactosemic patients and its association with 
a poor clinical outcome, the Q188R mutation has been extensively studied. The initial study 
using the COS cell expression system surprisingly showed that this mutation had about 10% 
of normal enzymatic activity (Reichardt et al., 1991). This result was not consistent with the 
clinical finding that patients homozygous for Q188R have no detectable enzyme activity in 
their red blood cells. Another study, carried out in a yeast model that was completely 
devoid of GALT activity, used a PCR-mediated SDM technique and clarified that  the Q188R 
mutation did cause loss of function of both human and yeast GALT (Fridovich-Keil et 
al.,1993b). Interestingly, this study also showed that the mutant yeast, with its loss of GALT 
activity, could not survive in galactose media if the Q188R missense mutation was 
introduced, while reconstitution of wild-type GALT resulted in normal growth (Fridovich-
Keil and Jinks-Roberson, 1993b). The confounding result of the first study is likely to be 
explained by the presence of endogenous GALT activity in the COS cells, highlighting the 
importance of studying mutations in a null background system, such as the gal7-deleted 
yeast model used in the second study. Alternatively, one should use purified mutant 
proteins in the analysis of the enzymatic activities. Subsequent studies further confirmed 
that the Q188R mutation not only totally abolishes GALT enzyme activity, but also acts as a 
partial dominant-negative mutation, as the heterodimer of Q188R/wild type has only  15% 
of wild-type activity (Fridovich-Keil et al., 1995a; Elsevier and Fridovich-Keil,1996). Kinetic 
analysis showed this mutation mainly causes impaired specific activity of the heterodimer 
without altering the KM for both substrates. In order to further understand how mutation at 
this site could affect the enzyme, Lai and coworkers mutated glutamine-188 (Gln188) to 
arginine and asparagine, respectively, through SDM (Lai et al., 1999). More detailed kinetic 
measurement showed that mutating glutamine to arginine or asparagine did not affect the 
first step of the double-displacement action (UDP-Glu to glu-1p). In fact, Q188R-GALT even 
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had a better Vmax as compared with the wild-type GALT. However, the Q188R mutation 
severely impaired the second step of the reaction. The crystal structures of E. coli GALT 
revealed that Gln168 (equivalent to Gln188 in human GALT) could stabilize the GALT-UMP 
intermediate through two hydrogen bonds formed between the amide side chain of Gln188 
and the phosphoryl oxygen of the UMP moiety (Wedekind et al., 1996). Through molecular 
modeling studies (or “virtual SDM”), Lai and coworkers changed glutamine to arginine and 
asparagine, respectively, and found that the number of hydrogen bonds formed between 
new amino acid residues and UMP moiety decreased to one, which could have destabilized 
the GALT-UMP intermediate required for the second displacement reaction (Lai et al., 1999). 
This destabilization was well manifested in the increased Vmax in the Q188R mutant in the 
first displacement reaction, as the destabilization speeded up the recycling of the enzyme for 
the first reaction (Lai et al., 1999). To complete the double-displacement reaction, a stable 
GALT-UMP intermediate was required to bind gal-1P, which was better accomplished by 
the two hydrogen bonds from glutamine than by the single hydrogen bond from arginine or 
asparagine. 
The S135L mutation was identified initially as a polymorphism with near normal enzymatic 
activity in the COS cell expression system (Reichardt et al., 1992). However, subsequent 
SDM studies in the yeast-expression system, defined this as a missense mutation that 
significantly impaired enzyme activity; but, unlike the Q188R mutation, it still had minor 
residual activity (Fridovich-Keil et al., 1995a). Later on, more detailed SDM and expression 
studies in yeast and E. coli heterologous expression systems revealed this mutation 
decreased the abundance of mutant protein about 2-fold compared with the wild type, as 
well as caused 10-fold decrease of specific activity with less than 2-fold of differences of KM 
values for both substrates (Lai and Elsas, 2001; Wells and Fridovich-Keil, 1997). There was 
no apparent difference in releasing glu-1P between the wild type and this mutant (Lai and 
Elsas, 2001). Mutating this serine to alanine, cysteine, histidine, threonine or tyrosine by 
SDM confirmed that a hydroxyl group is required on the side chain of amino acid 135, since 
only the threonine substitution resulted in active enzyme (Lai and Elsas, 2001). 
The K285N mutation compromises the activity of the enzyme, as well as its abundance, in 
the yeast expression system (Riehman et al., 2001). As for the N314D mutation, it was 
regarded as the reason of reduced enzymatic activity in Duarte 2 patients; but detailed 
enzymatic studies facilitated by SDM revealed that the mutation itself only causes isoelectric 
point shifting, without affecting protein abundance, subunit dimerization or activity 
(Fridovich-Keil et al., 1995b). The decrease in GALT activity observed in the Duarte type 2 
patients is likely caused by the 4-bp deletion at the promoter region associated with the 
N314D mutation, which abolishes the binding sites of two transcription factors to the GALT 
gene promoter (Carney, et al., 2009). The fact that the Los Angeles variant has normal 
activity in the erythrocytes supports this conclusion (Carney et al., 2009). 
3.3.2 Type II (GALK-deficiency) galactosemia 
More than 20 mutations associated with GALK deficiency have been reported to date. 
Through SDM studies, the majority of the mutations have been characterized. By expressing 
10 variant GALK enzymes in GALK-less E. coli, Timson and Reece showed that five of 
mutant GALK enzymes (P28T, V32M, G36R, T288M and A384P), which are associated with 
more severe clinical phenotypes and near-zero blood galactokinase levels, are insoluble 
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(Timson and Reece, 2003). Further studies showed that these mutations disrupted the 
secondary structure of the enzymes, which could result in misfolding of the protein (Thoden 
et al., 2005). Four of the five soluble mutants (H44Y, R68C, G346S, and G349S, but not 
A198V) have impaired enzymatic properties, such as increased KM for one or both substrates 
and decreased kcat. All five are associated with low blood enzyme levels and milder 
symptoms. From the crystal structure of human GALK, it is clear that His44, Gly346 and 
Gly349 are close to the active site. Additionally, these residues reside in the signature motif 
III of the GHMP kinase superfamily (Bork et al., 1993; Thoden et al., 2005). Therefore, it is 
not surprising that any changes in these resides would alter the kinetic parameters of the 
enzyme. As for A198V, its kinetic parameters are essentially indistinguishable from the 
wild-type enzyme. Compared to other mutations, from which patients will develop 
cataracts with high incidence within the first few years (without treatment), the A198V 
enzyme  causes only a moderate incidence of cataracts in later life. 
Similarly, Park and colleagues characterized another four missense mutations and one 
insertion (G137R, R256W, R277Q, V281M and 850_851insG) by expressing the corresponding 
mutated genes in COS7 cells (Park et al., 2007). The steady-state expression level of R256W 
was lower than that of wild type. The stability of the mutant enzyme was significantly 
reduced, and it had no detectable activity. No protein was detected for the insertion variant. 
The other three mutations manifested enzymes with similar expression levels in the soluble 
fraction, as compared to the wild-type level. However, the G137R and R277Q enzymes had 
approximately 10%-15% of wild-type activity, and no activity was detected for the V281M 
enzyme. 
3.3.3 Type III (GALE-deficiency) galactosemia 
GALE deficiency exists in a continuum, from generalized to peripheral via intermediate 
(Openo et al., 2006). If GALE is deficient in all tissues, it is classified as generalized; and, if it is 
only deficient in red and white cells but normal in other tissues, it is known as peripheral 
deficiency. It is possible that the presence of bi-allelic amorphic mutations is incompatible with 
life (Sanders et al., 2010). Infants with generalized deficiency develop disease on a lactose-
containing milk diet, while infants with peripheral disease remain well, at least in the newborn 
period. GALE deficiency has been extensively reviewed by Fridovich-Keil and coworkers 
(Fridovich-Keil et al., 1993a). Genomic GALE is about 5 kb in length, with multiple 
alternatively spliced transcripts. Some of the reported mutations are deposited in the HGMD 
database (http://www.hgmd.org/). Few case series have been reported, including a Korean 
study, reporting 37 patients with reduced GALE activity (Park et al., 2005), and two US-based 
studies, with one reporting 35 patients (Maceratesi et al., 1998) and the other, 10 patients 
(Openo et al.,2006). Others have reported a few cases (Alano et al., 1998; Wohlers et al., 1999). 
The V94M mutation has been reported in the homozygous state as being associated with 
generalized disease (Wohlers et al., 1999). In-depth studies of the V94M mutation through 
SDM in the yeast system showed that this mutation severely damages the specific activity of 
the enzyme predominantly at the level of VM without affecting its abundance and thermal 
stability (Wohlers et al., 1999; Wohlers and Fridovich-Keil, 2000). In the same study, the G90E 
mutation was shown to have zero enzymatic activity, rendering the mutant enzyme to high 
temperature and protease (Wohlers et al., 1999). A more recent study further confirmed the 
impact of V94M and G90E on VM (Timson 2005). Other missense mutations have not (yet) been 
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reported in patients, but they have been studied in vitro or in model systems. They are 
associated with severe enzyme deficiency; these include G90E and L183P (Quimby et al., 1997; 
Timson, 2005; Wohlers et al., 1999). Missense mutations associated with peripheral disease 
include R169W, R239W and G302A and have been described by Park and coworkers in 
individuals with peripheral GALE deficiency (Park et al., 2005). The K257R and G319E 
mutations have been described in African-Americans with peripheral deficiency (Alano et al., 
1998). The L183P mutation encodes an enzyme that experiences severe proteolytic degradation 
during expression and purification. Also the authors showed that enzymes resulting from the 
N34S, G90E and D103G mutations exhibited increased susceptibility to digestion in limited 
proteolysis experiments (Timson 2005). An earlier study on L183P and N34S using SDM in a 
yeast model revealed that the L183P-hGALE mutant demonstrated 4% wild-type activity and 
6% wild-type abundance, while N34S-hGALE demonstrated approximately 70% wild-type 
activity and normal abundance. However, yeast cells co-expressing both L183P-hGALE and 
N34S-hGALE exhibited only approximately 7% wild-type levels of activity, thereby 
confirming the functional impact of having both substitutions and raising the intriguing 
possibility that some form of dominant-negative interaction may exist between the mutant 
enzymes found in this patient (Quimby et al., 1997). Two other mutations, D130G and L313M, 
which are associated with intermediate epimerase deficiency, manifested enzymes with near 
normal GALE activity, but with compromised thermal stability and protease-sensitivity 
(Wohlers et al., 1999). Three other mutations associated with intermediate forms (S81R, T150M 
and P293L) were analyzed for their kinetic and structural properties in vitro and their effects on 
galactose-sensitivity of S. cerevisiae cells in the absence of Gal10p. All three mutations result in 
impairment of the kinetic parameters, principally the turnover number, kcat, compared to the 
wild-type enzyme. However, the degree of impairment was mild compared with that seen 
with the mutation V94M (Chhay et al., 2008). Studies are limited by the fact the many patients 
are compound heterozygotes and by the observation that dominant-negative interactions may 
be involved in some of these cases. 
4. Use of SDM in the understanding of catalytic mechanisms of the human 
GAL enzymes 
4.1 The issue 
Although the Leloir pathway is evolutionarily conserved and is indispensable for productive 
galactose metabolism, the catalytic mechanisms of the GAL enzymes are largely unknown. 
4.2 Research design 
Several groups have attempted to combine the techniques of SDM, analytical biochemistry 
and X-ray crystallography to advance the understanding of the catalytic mechanisms of the 
different GAL enzymes. 
4.3 The results 
4.3.1 GALK 
GALK converts galactose to gal-1P by transferring γ–phosphate group of ATP to the O1 
position of galactose. It belongs to a unique kinase superfamily – the GHMP kinase family, 
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which is named after four characteristic family members: galactokinase (GALK), homoserine 
kinase (HSK), mevalonate kinase (MVK) and phosphomevalonate kinase (PMVK) (Bork et 
al., 1993). This family of proteins was first identified by three highly conserved motifs 
among the four kinases mentioned above by sequence alignment and analysis. Motifs I and 
III are located at the N-terminal and C-terminal ends; and motif II, the most conserved, is 
located in the middle of the protein, with the consensus sequence of GLGSS(G/A/S) 
(Holden et al., 2004). 
Interestingly, two different catalytic mechanisms have been proposed for this family. A 
common catalytic strategy to achieve nucleophilic attack is to use a negative charged 
residue, such as aspartate or glutamate, to act as a Brønsted base. This catalytic base can 
then abstract a proton from the hydroxyl group of the substrate converting the weakly 
nucleophilic hydroxyl group into the more strongly nucleophilic alkoxide ion, which then 
attacks the electron-deficient phosphorus atom in ATP (Fig. 1A). In such systems, it is 
common to find positively-charged lysine or arginine residues close to the catalytic site to 
help stabilize the negative charges on the enzyme and the substrates. Studies on MVK 
suggest this enzyme follows this mechanism. The crystal structure of MVK reveals an 
aspartate (residue 204 in the rat enzyme) positioned to act as an active site base. There is also 
a lysine (residue 13 in rat MVK), which is close to both the putative catalytic aspartate 
residue and the hydroxyl group of the substrate (Fu et al., 2002; Yang et al., 2002). 
Replacement of the lysine residue with a methionine by SDM resulted in a reduced, but 
non-zero, rate (Vmax was reduced approximately 60-fold) (Potter et al., 1997). Similar results 
were observed when the equivalent lysine (residue 18) was changed to methionine in yeast 
mevalonate diphosphate decarboxylase (Krepkiy and Miziorko, 2004). These results are 
consistent with this positively-charged residue playing an assisting, but non-vital, role in 
catalysis. Crystal structures of GALK put it into this mechanism by revealing there are 
aspartate and arginine residues in the active center close to the galactose C1 hydroxyl group 
(Asp186 and Arg37 in the human structure, Asp183 and Arg36 in Lactococcus lactis) (Thoden and 
Holden, 2003; Thoden et al., 2005). Similarly,  changing Arg37 of human GALT to alanine 
resulted in a nearly inactive enzyme; and lysine resulted in compromised kcat and KM for 
galactose (Tang, et al., 2010). 
In contrast, phosphoryl transfer in HSK has been suggested to occur by direct nucleophilic 
attack on the γ-phosphate group of ATP by the δ-hydroxyl of homoserine (Fig. 1B) 
(Krishna et al., 2001). In this mechanism, the latter is stabilized by the formation of a 
hydrogen bond to a neighboring asparagine residue (Asn141), which is not conserved in the 
superfamily. Catalysis is proposed to be assisted through activation of the γ-phosphate of 
ATP by the magnesium ion, which is coordinated by a conserved glutamate residue 
(Glu130) with the deprotonation of the δ-hydroxyl possibly involving the γ-phosphate 
(Krishna et al., 2001). 
4.3.2 GALT 
GALT catalyzes the transfer of the uridine monophosphate group (UMP) from uridine 
diphosphate-glucose (UDP-Glu) to gal-1p to form uridine diphosphate-galactose (UDP-Gal) 
and glucose-1-phosphate (glu-1P) (Kalckar et al., 1953). The reaction follows the double 
displacement mechanism as shown in Fig. 2 (Arabshahi et al., 1986). The most characteristic  
 
Use of Site-Directed Mutagenesis in the Diagnosis, Prognosis and Treatment of Galactosemia 
 
241 
 
Fig. 1. Catalytic mechanisms proposed for GHMP kinase. A. The enzyme catalyzes the 
reaction through an active base residue R1, which attracts a proton from the substrate R3, 
converting the weakly nucleophilic hydroxyl to an alkoxide ion, which attacks the γ-
phosphate of ATP. A positively charged residue R2, sits close to the catalytic residue and 
stabilizes the alkoxide ion. B. There is no active base residue in the active center, the 
substrate directly attacks the γ–phosphate of ATP. 
feature of the reaction is forming a covalent UMP-enzyme intermediate (Arabshahi et al., 
1986). The intermediate was isolated by gel permeation chromatography in reaction 
mixtures containing the enzyme and radiolabeled UDP-Glu, and the radiolabeled 
intermediate could react with gal-1P or glu-1P to form the corresponding radiolabeled UDP 
sugar (Wong, et al., 1977a). This intermediate is very fragile in slightly acidic solutions but 
quite stable in strong basic solutions (Wong et al., 1977a; Yang and Frey, 1979), which 
indicates the intermediate is phosphoramides. Further degradation study of this 
intermediate confirmed that the nucleophile in GALT, to which the uridylyl group is 
bonded in the uridylyl-enzyme intermediate, is imidazole N3 of a histidine residue (Yang 
and Frey, 1979). 
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Fig. 2. Double displacement reactions of GALT. GALT binds to UDP-Glu to form a GALT-
UDP-Glu intermediate. Glu-1-P is subsequently released, whereas the enzyme remains 
bound to UMP. Gal-1-P then reacts with the enzyme-UMP intermediate to form UDP-Gal, 
freeing the GALT enzyme for continued catalysis. kn and k−n denote rate constants of the 
forward and reverse reactions. 
Substituting each of the 15 histidine residues in E. coli GALT with asparagines by SDM, 
proved that His164 and His166 were the only essential histidine residues in the enzyme (Field 
et al., 1989). In order to identify which of these two residues is the catalytic residue, two 
more specific mutations were introduced by SDM, H164G and H166G, which resulted in loss 
of function of the enzyme because of the missing imidazole ring of histidine, which might be 
filled and salvaged by adding exogenous imidazole ring. The experimental results showed 
that the activity of the H166G mutant could be recovered by adding exogenous imidazole 
ring, while mutant H164G could not. Therefore, His166 provides the catalytic nucleophilic 
imidazole ring in the reaction (Kim et al., 1990). 
Also, as mentioned earlier, by mutating Gln188 of human GALT (equivalent to Gln168 in E. coli 
GALT), the most common mutation found in Type I Galactosemia, to arginine and asparagine, 
respectively, we were able to determine that glutamine at position 188 stabilizes the UMP-
GALT intermediate through hydrogen bonding and enables the double displacement of both 
glucose-1-phosphate (glu-1P) and UDP-galactose. The substitution of arginine or asparagine at 
position 188 reduces hydrogen bonding and destabilizes UMP-GALT. The unstable UMP-
GALT allows single displacement of glu-1P with release of free GALT but impairs the 
subsequent binding of gal-1P and displacement of UDP-Gal (Lai, et al., 1999).  
4.3.3 GALE 
GALE catalyzes the inter-conversion of UDP-Glu and UDP-Gal to finish the Leloir pathway 
of galactose metabolism. There are four key steps for the reaction of GALE as shown in Fig. 
3: (1) abstraction of the 4‘-hydroxyl hydrogen of the sugar by an enzymatic base, (2) transfer 
of a hydride from C4 of the sugar to the C4 of NAD+ leading to a 4‘-ketopyranose 
intermediate and NADH, (3) rotation of the resulting 4‘-ketopyranose intermediate in the 
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active site, and (4) return of the hydride from NADH to the opposite face of the sugar 
(Maitra and Ankel, 1971). When purified, this enzyme contains tightly bound NAD+, which 
functions as an essential coenzyme to catalyze the reaction (Darrow and Rodstorm, 1968). 
The binding of the UDP group is strong, while binding with the galactosyl, glucosyl and 4-
ketohexopyranosyl moieties is weak (Kang et al., 1975; Wong and Frey, 1977b). Early study 
on the catalytic mechanism of GALE focused on Lys153, since it is close to the NAD+, and the 
positively-charged ammonium group of Lys153 may perturb the electron distribution in the 
nicotinamide ring of NAD+ through charge repulsion upon substrate binding (Swanson and 
Frey, 1993). Replacing this residue with alanine or methionine renders the inability of the 
mutant proteins to be reduced by the sugar in the presence or absence of UMP. As a result, 
the catalytic activities of the mutants decreased by a factor over 1000. Also the purified 
mutant contained much less NADH as compared with wild type (Swanson and Frey, 1993). 
These results indicate that Lys153 plays an important role in the UMP-dependent reduction 
of GALE-NAD+. Further studies identified two more important residues, Tyr149 and Ser124, 
which are involved in glucose moiety binding (Thoden et al.,  1996). SDM studies on the 
latter two residues revealed that that Tyr149 provides the driving force for general acid-base 
catalysis, while Ser124 plays an important role in mediating proton transfer (Liu et al., 1997). 
The crystal structure of human GALE confirmed that Tyr149 (Tyr157 for human GALE) sits at 
the proper position to interact directly with the 4’-hydroxyl group of the sugar and attracts 
the proton from the hydoxy group and transfers it to NAD+ (Thoden et al., 2000). 
Unlike what was observed for the E. coli enzyme, the human enzyme can also convert UDP-
N-acetylglucosamine (UDP-GlcNAc) to UDP-N-acetylgalactosamine (UDP-GalNAc) 
(Kingsley et al., 1986; Piller et al., 1983). Through structure analysis and alignment, 
investigators found that, when the human enzyme equivalent of Tyr299 in the E. coli protein 
is replaced with a cysteine residue (Cys307), the active site volume for the human protein is 
calculated to be approximately 15% larger than that observed for the bacterial epimerase 
(Thoden 2001). Substituting Tyr299 of E. coli GALE with a cysteine residue by SDM confers 
UDP-GalNAc/UDP-GlcNAc converting activity to the bacterial enzyme with minimal 
changes in its three-dimensional structure. Specifically, although the Y299C mutation in the 
bacterial enzyme resulted in a loss of epimerase activity with regard to UDP-Gal by almost 
5-fold, it resulted in a gain of activity against UDP-GalNAc by more than 230-fold (Thoden 
et al., 2002b). 
5. Use of SDM in the development of novel treatment of Type I (classic or 
GALT-deficiency) galactosemia 
5.1 The issues  
Unlike Type II or the peripheral Type III Galactosemia, patients with Type I (GALT-
deficiency) Galactosemia, also the most common type of Galactosemia, suffer a range of 
debilitating long-term complications, which include premature ovarian insufficiency, 
learning deficits, ataxia and speech dyspraxia (Lai et al., 2009; Berry and Elsas, 2011). The 
current galactose-restricted diet fails to prevent these complications, and the medical/ 
patient communities are yearning for a more effective therapy. The causes of these organ-
specific complications remain unknown, but there is a strong association with the 
intracellular accumulation of gal-1P. But what is the source of gal-1P in these patients with 
Classic Galactosemia if they limit their galactose intake?  Recent studies have shown that the 
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patients on a galactose-restricted diet are never really “galactose-free. A significant amount 
of galactose is found in non-dairy foodstuffs, such as vegetables and fruits (Berry et al., 1993; 
Acosta and Gross, 1995). More importantly, galactose is produced endogenously from the 
natural turnover of glycolipids and glycoproteins (Berry et al., 1995). Using isotopic labeling, 
Berry and coworkers demonstrated that a 50kg adult male could produce up to 2 grams of 
galactose per day (Berry et al., 1995, 2004). Once galactose is formed intracellularly, it is 
converted to gal-1P by GALK and in GALT-deficient patient cells. As a result, gal-1P is 
concentrated more than one order of magnitude above normal, even with strict adherence to 
a galactose-restricted diet. Accumulation of gal-1P is regarded as a major, if not sole, factor 
for the chronic complications seen in patients with Classic Galactosemia, as suggested by 
both clinical observation and experimental results from yeast models. Patients with 
inherited deficiency of GALK, who do not accumulate gal-1P, do not experience the brain 
and ovary complications seen in GALT-deficient patients (Gitzelmann et al., 1974; 
Gitzelmann 1975; Stambolian et al., 1986). While gal7 (i.e, GALT-deficient) mutant yeast 
stops growing upon galactose challenge, a ga17 ga11 double mutant strain (i.e, GALT- and 
GALK-deficient) is no longer sensitive to galactose (Douglas and Hawthorne, 1964, 1966). 
Based on these observations, in conjunction with dietary therapy, inhibiting GALK activity 
with a safe small-molecule inhibitor might prevent the squeals of chronic gal-1P exposure in 
patients with Classic Galactosemia. 
 
Fig. 3. Catalytic mechanism of GALE. 
5.2 Research design 
For the past few years, our group has conducted high-throughput screening (HTS) of small 
molecule compounds, which could inhibit human GALK enzyme in vitro (Tang et al., 2010; 
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Wierenga et al., 2008). To date, we have screened over 300,000 compounds of diverse 
chemical structures and identified a few promising hit compounds for further 
characterization. One of the characterization steps involved the use of SDM to change the 
respective amino acids of the GALK active site in order to confirm the predicted molecular 
interactions between the selected inhibitors and it target, GALK, through high-precision 
docking programs such as GLIDE (Schrödinger). Another characterization step that is 
noteworthy to mention is the assay for the kinase selectivity of the selected GALK inhibitors. 
As alluded above, GALK belongs to a unique small molecule kinase family, the GHMP 
kinase family (Bork et al., 1993). While the substrates of the GHMP kinases differ widely, the 
ATP-binding sites of the enzymes share a significant degree of structural homology (Tang et 
al., 2010). It is, therefore, important to ensure our selected GALK inhibitors did not cross-
inhibit other GHMP kinases or other kinases in general. 
5.3 The results 
Selectivity is always one of the most important properties for developing therapeutic kinase 
inhibitors because of potential side-effects from unwanted inhibition of other kinases. 
During the characterization phase of our hit compounds, we found six compounds that 
selectively inhibit GALK but not any of the other GHMP kinases. These included MVK, 
which shares a high degree of structural similarity with GALK (Tang et al., 2010). In order to 
understand what structural elements conferred the specificity of these compounds, we 
aligned the crystal structure of human GALK and human MVK and focused on the ATP-
binding site. Eight amino acid residues and the L1 loop were found to be different in these 
two kinases. SDM was employed to mutate each residue individually or the L1 loop, and the 
effects of the changes on the inhibitory capabilities of the compounds were tested. Two 
compounds were found to be affected by the mutation S140G (Table 1) (Tang et al., 2010). 
Ser140 of GALK resides in the signature motif of the GHMP kinase family, Motif II; but this 
amino acid is not conserved among the GHMP kinases. GALK is the only member that has a 
serine at this site. This could explain the selectivity of these two compounds. Furthermore, 
computational molecular docking confirmed that these two compounds interacted with 
Ser140 through hydrogen bonds; substituting serine with glycine abolished the hydrogen 
bonds and totally compromised the binding of the compounds to the enzymes. 
Our use of SDM in the characterization of promising GALK inhibitors not only helped 
identify and confirm the amino acids of GALK with which these small molecules interact, 
but also exemplified a more rapid and cost-effective way to study the structural interactions 
between small molecule modifiers and their targets. This novel approach is particularly 
useful when large-scale co-crystallization projects are not feasible. These studies paved the 
way for more in-depth investigations to identify the structural determinants required for the 
inhibitor selectivity of GALK and GHMP kinases. 
6. Concluding remarks 
Using the disease Galactosemia as an example, we showed that site-directed mutagenesis 
(SDM) plays a vital role in biomedical research. As in the case of  Galactosemia, in which 
the diagnosis begins at the bedside of the affected newborns, SDM can be employed in 
every step of basic and translational research in an attempt to improve the prognosis and 
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treatment of the patients. Further, not only did we show that SDM can be applied in 
traditional applications, such as expression analysis, we have also expanded its use in 
innovative drug design and the basic understanding of kinase inhibitor selectivity. 
 
Mutations 
kcat 
(S-1) 
KM 
of ATP 
(µM) 
KM 
of 
Galactose 
(µM) 
Effects on IC50 
of compound 1
Effects on IC50 
of compound 4
Effects on IC50 
of compound 
24 
T77L 4.1 218.4 1305.2 None None None 
S79N 4.8 303.4 1227.3 None None None 
L145Y 11.6 259.7 222.7 None None None 
L145A 6.4 379.9 356.8 None None None 
W106A 
No protein 
expression 
- - - - - 
W106T 
No protein 
expression 
- - - - - 
Y109L 43.2 70.2 963.2 None None None 
Y109A 8.7 579.3 268.7 None None None 
GALK Loop 
to MVK Loop 
0.1 695.4 1857.3 None None None 
S140G 2.1 8.2 141.9 None 
Increased 10-
fold 
Increased 20-
fold 
L135P 13.3 51.1 544.9 None None None 
R37K 0.4 6.4 623.8 None None None 
R37A No activity - - - - - 
WT 17.5 20.9 319 - - - 
Table 1. Effect of amino acid changes in human GALK on their enzymatic properties and the 
IC50 of selected inhibitors 
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